Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757

International Immunopharmacology

Volumn 10, Issue 8, 2010, Pages 837-842

  Stenström, Martin ^a,b   Anderson, Per ^a,c   Eroukhmanoff, Lena ^a   Leanderson, Tomas ^a   Ivars, Fredrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b Active Biotech Research AB   (Sweden)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Carboxamide; Dendritic cell; Spleen

Indexed keywords

ABR 215757; AMIDE; CD4 ANTIGEN; QUINOLONE 3 CARBOXAMIDE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPH NODE; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTIGENS, CD4; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; QUINOLINES;

EID: 77954958927     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.011     Document Type: Article

References (34)

1. Gross D.J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994, 37:1195-1201.
2. Kleinau S., Larsson P., Bjork J., Holmdahl R., Klareskog L. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin Exp Immunol 1989, 78:138-142.
3. Tarkowski A., Gunnarsson K., Stalhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB×NZW) F1 hybrid mice. Immunology 1986, 59:589-594.
4. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 1993, 34:654-660.
5. Coutant R., Landais P., Rosilio M., Johnsen C., Lahlou N., Chatelain P., et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998, 41:1040-1046.
6. Noseworthy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A., Gjorstrup P., et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
7. Wolinsky J.S., Narayana P.A., Noseworthy J.H., Lublin F.D., Whitaker J.N., Linde A., et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000, 54:1734-1741.
8. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
9. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., Astrom M., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002, 130:163-172.
10. Runstrom A., Leanderson T., Ohlsson L., Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006, 173:69-78.
11. Bjork P., Bjork A., Vogl T., Stenstrom M., Liberg D., Olsson A., et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009, 7:e97.
12. Hogg N., Allen C., Edgeworth J. Monoclonal antibody 5.5 reacts with p8, 14, a myeloid molecule associated with some vascular endothelium. Eur J Immunol 1989, 19:1053-1061.
13. Zwadlo G., Schlegel R., Sorg C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J Immunol 1986, 137:512-518.
14. Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997, 272:9496-9502.
15. Fogg D.K., Sibon C., Miled C., Jung S., Aucouturier P., Littman D.R., et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006, 311:83-87.
16. Varol C., Landsman L., Fogg D.K., Greenshtein L., Gildor B., Margalit R., et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med 2007, 204:171-180.
17. Onai N., Obata-Onai A., Schmid M.A., Ohteki T., Jarrossay D., Manz M.G. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol 2007, 8:1207-1216.
18. Diao J., Winter E., Cantin C., Chen W., Xu L., Kelvin D., et al. In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol 2006, 176:7196-7206.
19. Liu K., Victora G.D., Schwickert T.A., Guermonprez P., Meredith M.M., Yao K., et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009, 324:392-397.
20. Naik S.H., Metcalf D., van Nieuwenhuijze A., Wicks I., Wu L., O'Keeffe M., et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 2006, 7:663-671.
21. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
22. Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004, 172:4410-4417.
23. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
24. Kamath A.T., Pooley J., O'Keeffe M.A., Vremec D., Zhan Y., Lew A.M., et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000, 165:6762-6770.
25. Liu K., Waskow C., Liu X., Yao K., Hoh J., Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 2007, 8:578-583.
26. Hagnerud S., Manna P.P., Cella M., Stenberg A., Frazier W.A., Colonna M., et al. Deficit of CD47 results in a defect of marginal zone dendritic cells, blunted immune response to particulate antigen and impairment of skin dendritic cell migration. J Immunol 2006, 176:5772-5778.
27. Van V.Q., Lesage S., Bouguermouh S., Gautier P., Rubio M., Levesque M., et al. Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs. EMBO J 2006, 25:5560-5568.
28. De Smedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., De Baetselier P., et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996, 184:1413-1424.
29. McLellan A.D., Kapp M., Eggert A., Linden C., Bommhardt U., Brocker E.B., et al. Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood 2002, 99:2084-2093.
30. Nolte M.A., Arens R., Kraus M., van Oers M.H., Kraal G., van Lier R.A., et al. B cells are crucial for both development and maintenance of the splenic marginal zone. J Immunol 2004, 172:3620-3627.
31. Kamath A.T., Henri S., Battye F., Tough D.F., Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002, 100:1734-1741.
32. Martin F., Oliver A.M., Kearney J.F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001, 14:617-629.
33. Chen Y., Pikkarainen T., Elomaa O., Soininen R., Kodama T., Kraal G., et al. Defective microarchitecture of the spleen marginal zone and impaired response to a thymus-independent type 2 antigen in mice lacking scavenger receptors MARCO and SR-A. J Immunol 2005, 175:8173-8180.
34. Karlsson M.C., Guinamard R., Bolland S., Sankala M., Steinman R.M., Ravetch J.V. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med 2003, 198:333-340.